Patent · US Active

Modified cell with enhanced functionality and cellular therapy thereof

US11833174B2 · kind B2 · utility

0Cited by

0References

17Claims

0Family size

Assignee

Innovative Cellular Therapeutics Holdings, Ltd. · KY

Inventors

Zhiyuan Cao · Hangzhou City, CN
Chengfei Pu · Shanghai, CN
Dongqi Chen · Shanghai, CN
Wei Ding · Salt Lake City, US

Key dates

Filing date	Sep 17, 2020
Grant date	Dec 5, 2023
Priority date	—
Expiry date	Nov 14, 2041

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2319/33
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Embodiments relate to a modified cell comprising a polynucleotide encoding a dominant negative form of Death receptor 5 (DR5). In embodiments, the modified cell further comprises a chimeric antigen receptor (CAR) and/or a modified TCR.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.